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ABSTRACT 
Despite efforts to control synthetic cannabinoids, clandestine manufacturers 
continue to modify their structures to avoid legal consequences, creating an ever-changing 
analytical target for forensic laboratories (1).  Forensic toxicology laboratories often lack 
the needed resources or do not have the capabilities to test for these compounds and 
metabolites, requiring specimens to be submitted to reference laboratories (2).  Drug 
stability can be affected by long storage times, temperature and preservatives (3).  Although 
these factors can be controlled, systematic research is necessary to identify their impacts 
on the stability of these new synthetic cannabinoids that are continually emerging.   
The purpose of this research is to assess the stability of 17 synthetic cannabinoids 
in human whole blood and 10 synthetic cannabinoid metabolites in human urine using 
liquid chromatography-tandem mass spectrometry (LC-MS/MS) over thirty-five weeks.  
The analysis methods were validated in accordance to the Academy Standards Board 
(ASB) method validation guidelines for quantitative analysis and stability evaluation of the 
following analytes in blood: 4-cyano CUMYL-BUTINACA, ADB-PINACA, EMB-
FUBINACA, JWH-250, MO-CHMINACA, 5-fluoro-3,5-ABPFUPPYCA, 5-fluoro ADB-
PINACA, APP-PICA, CUMYL-THPINACA, PB-22, XLR11, 5-fluoro PY-PINACA, 
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MDMB-FUBICA, MEP-CHMICA, NM2201, RCS-8, and UR144.  The stability analysis 
in urine includes the following metabolites: 5-fluoro MDMB-PICA metabolite 7, 5-fluoro 
PB-22 3-carboxyindole, AB-FUBINACA metabolite 3, ADB-PINACA N-(4-
hydroxypentyl), ADB-PINACA pentanoic acid, UR-144 Degradant N-pentanoic acid, PB-
22 N-(5-hydroxypentyl), MDMB-FUBICA metabolite 3, UR-144 N-(5-hydroxypentyl), 
and JWH-250 N-pentanoic acid.  
Research samples were prepared by spiking with certified reference standards 
(Cayman Chemical, Ann Arbor, MI, USA) of each select synthetic cannabinoid in certified 
drug-free human whole blood (Boston Medical Center, Boston, MA, USA; Biological 
Specialty Corporation, Colmar, PA) and drug-free urine that was received as donations 
following the approved Institutional Review Board guidelines (Boston University School 
of Medicine, Boston, MA, USA).  Blood samples were aliquoted into 6 mL BD Vacutainer 
Plastic Collection Tubes (Fisher Scientific, Waltham, MA, USA) and urine samples were 
stored in 15 mL Falcon Conical Centrifuge Tubes (Fisher Scientific, Waltham, MA, USA).  
Stability under room temperature (20ºC), refrigerator (4ºC), and freezer (-20ºC) at low and 
high concentrations were evaluated at select time points.  A 5% solution of potassium 
oxalate and sodium fluoride or ethylenediaminetetraacetic acid (EDTA) was added to the 
preserved blood samples by the manufacturer prior to storage.  The anticoagulant, 
potassium oxalate, was only added in solution to the preserved samples whereas none was 
added to the nonpreserved samples.  Short-term urine samples were preserved with 1% of 
sodium fluoride prior to storage.  Extraction of analytes was conducted using supported-
liquid extraction (SLE) ISOLUTE 1 mL cartridges (Biotage, Charlotte, NC, USA) and 
vii 
reconstituted in 100 µL of 50:50 mixture of 0.1% formic acid in millipore deionized water 
and 0.1% formic acid in acetonitrile (Fisher Scientific, Waltham, MA, USA).   
Analysis was performed in triplicate using a reverse-phase C18 column (Waters 
XBridge C18 3.5 µM, 2.1 x 50 mm, Milford, MA, USA) on the Shimadzu Prominence 
Ultra-Fast Liquid Chromatography (UFLC, Kyoto, Japan) with SCIEX 4000 Q-Trap 
Electrospray Ionization Tandem Mass Spectrometry (ESI/MS/MS, Waltham, MA, USA) 
in positive ionization mode.  The total run time was 8 minutes with a flow rate of 0.6 
mL/min and injection volume of 10 µL.  Linear calibration curves for each analyte with 
the exception of a quadratic regression for PB-22, all had acceptable R2 values > 0.99 using 
a weighting factor of 1/x.  A linear dynamic range of 0.5 – 25 ng/mL was used for all 
analytes in blood except for NM2201 and APP-PICA with a limit of quantitation (LOQ) 
of 0.1 ng/mL and MO-CHMINACA with a working range of 0.5 – 15 ng/mL. A linear 
working range of 5 – 40 ng/mL was utilized for all metabolites in urine.  No signs of 
carryover were observed.  In general, analytes were considered stable if the average area 
ratio between the analyte and internal standard at the time point was within ± 20% of the 
average area ratio response at time point zero. In some cases, it was necessary to evaluate 
the complete picture of the stability data by reviewing analyte area, concentration, and 
overall stability data trend between timepoints at the low and high concentrations. In 
certain situations, an analyte was considered stable even if specific timepoints for a 
concentration were outside the ±20% range. For example, in cases where one concentration 
at a timepoint was within the ±20% range and the other concentration fell within ±30% 
range the analyte was considered stable overall.  
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 Long-term stability results revealed that all synthetic cannabinoids were stable at 
21 to 35 weeks in frozen blood preserved with sodium fluoride except for APP-PICA.  The 
preservatives are recommended to be added to blood to reduce the possibility of matrix 
inferences and minimize detrimental impacts on the stability of synthetic cannabinoids.  
Analytes experienced lower degradation in the order of samples that were kept frozen, 
refrigerated, and then at room temperature.  Blood analytes that were stable up to 35 weeks 
in freezer generally had a core structure of a carbonyl substituent on a pyrazole or pyrrole 
with surrounding nonpolar groups; whereas compounds with two polar carbonyl functional 
groups present were found to experience degradation much earlier at 1 week or less in room 
temperature and refrigerator storage conditions.  5-fluoropentyl analogs, like XLR11 and 
5-fluoro ADB-PINACA, in comparison to their counterpart analyte, UR144 and ADB-
PINACA, were unstable at earlier time points under all storage conditions.  Instability in 
the majority of the urine metabolites was not observed until after 9 weeks and was generally 
consistent across all storage conditions. 
 The validated methods demonstrate a sensitive and reliable way to positively 
identify 17 different synthetic cannabinoids in human whole blood and 10 synthetic 
cannabinoid metabolites in urine for rapid time stability analysis at various storage 
conditions.  The use of SLE improved sample preparation efficiency by decreasing the 
extraction time from 1 hour to 30 minutes compared to traditional extraction methods, such 
as solid-phase extraction (SPE) and liquid-liquid extraction (LLE).  Further studies into 
additional matrices, such as oral fluid, longer storage times, and other emerging synthetic 
cannabinoid analytes would expand the scope of this research. 
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1. INTRODUCTION 
1.1 History and Background 
 The plant Cannabis sativa, more commonly known as marijuana, was first 
documented for its medicinal properties that traced back to more than 5,000 years ago near 
ancient China (4, 5). Within the last half century, cannabis has been widely documented to 
relieve chronic pain, treat diseases such as Parkinson’s or HIV/AIDS, as well as alleviate 
nausea and vomiting for chemotherapy patients (4, 5). The Drug Enforcement 
Administration (DEA) classifies marijuana as a Schedule I controlled substance with no 
currently accepted medical use and high potential for abuse (6). However, many states 
throughout the USA, including but not limited to California, Colorado and Massachusetts, 
have gone as far as to decriminalize marijuana for recreational use. Controversy 
surrounding the national stigma that marijuana serves as a gateway drug to stronger and 
more harmful drugs and can cause concerns for dependence or whether marijuana truly 
possesses therapeutic effects that can help individuals with symptom relief and disease 
demonstrates the complexity behind the plant-based therapy (4). This debate has launched 
millions of dollars of funding into the advancing research on the pharmacology and effects 
of cannabinoids. In 2017, the National Institute of Health (NIH) has invested $140 million 
into 330 different cannabinoid projects (7). The research ranges significantly by examining 
the therapeutic properties of cannabinoids, societal and health impacts, the physiological 
systems the drugs target or the stability of the analytes in different biological matrices 
concerning casework backlogs (7).  
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1.2 Synthetic Cannabinoids 
1.2.1 Synthetic Cannabinoids as Designer Drugs 
Cannabinoids are classified in three main categories: endogenous cannabinoids, 
phytocannabinoids, and synthetic cannabinoids. Endogenous cannabinoids, like 
anandamide, are found naturally in the body; whereas phytocannabinoids are naturally 
occurring compounds exclusively found in the plant source Cannabis sativa. Examples 
include its main psychoactive component, delta-9-tetrahydrocannabinol (Δ9-THC), and 
cannabidiol (CBD).  Synthetic cannabinoids (SC) are synthesized substances that are 
commonly sold as “legal highs” in order to circumvent the law (7). These compounds vary 
significantly in molecular structure but have the potential to either mimic or produce 
stronger effects than that of cannabis. The success of these designer SCs are due to the 
diverse structures that may arise that are not currently controlled by federal regulations. 
Early synthetic cannabinoids were first researched by pharmaceutical companies and 
organic chemists to find alternative treatments for HIV/AIDS and chemotherapy. In the 
early 1980s, Pfizer discovered cyclohexylphenols that were used in the localization of 
cannabinoid receptors (1, 8). At Hebrew University, Raphael Mechoulam synthesized 
analogs with a dibenzopyran core that were structurally similar to Δ9-THC. In the 1990s, 
an organic chemistry professor at Clemson University by the name of John W. Huffman 
(JWH) created the most extensive synthetic cannabinoid library that diverged from the 
classical dibenzopyran core structure (1, 8). These novel JWH cannabinoids possess similar 
chemical properties to Δ9-THC, the main psychoactive component in marijuana, despite 
their structural differences. Unfortunately, Huffman’s cannabinoid research had sparked 
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an online market for legal cannabis alternatives sold as natural herbs, incense, “Spice” or 
“K2”. Alexandros Makriyannis, a Northeastern University chemistry professor, also 
notably developed additional synthetic cannabinoid derivatives, such as the carboxamide 
analog AB-FUBINACA (1, 8).  
 
1.2.2 Chemical Structure 
The main psychoactive constituent of cannabis has a similar chemical structure to 
anandamide, an endocannabinoid produced naturally in the brain, allowing Δ9-THC to be 
easily recognized by the body and thus alter normal brain communication and senses (9). 
Dibenzopyran cannabinoids, including the analogs synthesized by Raphael Mechoulam, 
are highly potent agonists with the same structural core as Δ9-THC (1). The 
aminoalkylindole analogs derived from JWH generally had a carbonyl connecting an 
indole to another heterocyclic ring, becoming what are known as napthoylindoles, 
benzoylindoles, phenylacetylindoles and cycloalkylindoles. When clandestine laboratories 
began modifying structures to circumvent the law, many of the emerging synthetic 
cannabinoids tended to possess stronger euphoric and psychotropic effects than the typical 
phytocannabinoids found in marijuana as a result. A vast range of different synthetic 
cannabinoids are currently available, often created by replacing the indole heterocyclic 
core with an indazole (10). Among all of the synthetic cannabinoids that were studied in 
this project, the analytes were phenylacetylindole, cycloalkylindole, quinolinyl and 
carboxamide cannabinoid derivatives.  
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1.2.3 Pharmacology and Effects 
Cannabinoids are generally defined as any substance that binds to the cannabinoid 
receptors, eliciting similar pharmacodynamic properties as Δ9-THC. The CB1 and CB2 
cannabinoid receptors are linked to the inhibition of adenylyl cyclase by activation of the 
G-protein coupled receptor system; thereby decreasing cyclic adenosine monophosphate 
(cAMP) production levels and evoking cannabimimetic responses (1, 11). The cannabinoid 
receptor CB1 is predominantly expressed in the central nervous system (CNS); whereas 
the second cannabinoid receptor CB2 is principally expressed in the peripheral nervous 
system (PNS). Extracts of Cannabis sativa, containing a complex mixture of Δ9-THC and 
other phytocannabinoids, interact with both cannabinoid receptors (11, 12).  
Popularity of synthetic cannabinoid usage stems from ability to experience similar to 
stronger “cannabis-like” effects with smaller chances of being detected from a simple urine 
test. High availability and low prices expose users to more severe acute and long-term side-
effects of synthetic cannabinoids. Cannabis may cause consumers to experience a variety 
of effects such as hallucinations, paranoia, and mood disorders. It may also increase risks 
for cardiovascular disease and lung cancer, as well as impairment of thinking, judgment 
and memory. Synthetic cannabinoids can intensify these health risks through its stronger 
binding affinity and selectivity to the cannabinoid receptor sites, even potentially causing 
permanent physical and psychological damage. (13). 
Since CB1 receptors are primarily expressed at the brain while CB2 receptors are in 
the immune system, CB2-selective agonists are being explored for its therapeutic potential 
in efforts to avoid undesired psychotropic effects that may accompany CB1 activating 
5 
cannabinoids. Scientific evidence supports that the activation of CB2 receptors does not 
produce the negative CNS effects (11, 14). Since Δ9-THC and the majority of synthetic 
cannabinoids have a stronger binding affinity to the CB1 than the CB2 receptor, the goal 
for future research and compound development is to explore any CB2 exclusive or non-
psychoactive cannabinoids (1, 14). Extensive funding into the research of Cannabidiol 
(CBD) has revealed evidence that this phytocannabinoid appears to possess antipsychotic 
properties and counteract cognitive impairment associated with Δ9-THC. CBD has been 
reported to significantly reduce pain with the administration of Sativex®, a 1:1 THC-CBD 
mixture; however, additional research is needed for long-term chronic pain relief of CBD 
alone (12, 13). 
 
1.2.4 Arise in Synthetic Cannabinoid Abuse 
Cannabis is the most commonly utilized illicit drug worldwide (15). According to a 
2016 report by the Substance Abuse and Mental Health Services Administration 
(SAMHSA), 14.8% of people tested within the age of 12 to 17 have reported trying 
cannabis at least once in their lifetime (15). From 2010 to 2011, emergency visits related 
to synthetic cannabinoids had drastically increased from 11,406 to 28,531 in which three-
fourths were from 12 to 29 years of age; Poison Control Center calls had also significantly 
increased from about 2900 to 7000 in response to adverse SC effects (16). Synthetic 
cannabinoids are appealing to consumers, especially young people, since SCs can 
reproduce similar to greater effects to smoking marijuana, are readily accessible, as well 
as difficult for law enforcement due to its detectability issues with regard to the growing 
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range of new SC analogs (16, 17). Lack of knowledge and research on the potential risks 
involved with acute and prolonged use makes synthetic cannabinoids a major public health 
concern.  
 
1.2.5 Legislative Control and Federal Scheduling 
In 1971, the Controlled Substances Act (CSA) became effective by adding heroin, 
marijuana, ecstasy, and gamma hydroxybutyric acid (GHB) as Schedule I controlled 
substances. Drugs, substances and chemicals were classified based on its accepted medical 
use and potential for abuse or dependency into five distinct categories. Under federal law, 
marijuana remains a Schedule I controlled substance despite state laws that have passed 
for medicinal or recreational use of cannabis (18). The Drug Enforcement Administration 
has the right to criminally prosecute individuals for any controlled substances that are 
structurally or pharmacologically similar to a Schedule I drug (7). In 2011, the DEA began 
its first efforts to temporary place synthetic cannabinoids as Schedule I controlled 
substances which include JWH-018, JWH-073, JWH-200, CP-47,497 and CP-47,497 C8 
homologue (19). As more structurally-diverse synthetic cannabinoids emerge, the DEA 
continues to add new Schedule I analogs under the CSA that were not necessarily 
considered illegal under existing regulations. One of the analytes evaluated in this study, 
4-cyano CUMYL-BUTINACA, had just temporarily scheduled last year in July 2018, 
demonstrating the importance of facilitating research on the various synthetic cannabinoids 
readily available (20). 
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1.3 Challenges 
1.3.1 Novel Psychoactive Substances 
Novel psychoactive substances (NPS), often referred as “designer drugs” or “legal 
highs”, are recreational drugs designed to imitate the effects of existing controlled 
substances. However, NPS can have higher potency and selectivity than the original illicit 
drug, resulting in more powerful and unpredictable side effects. The four main NPS drug 
groups abused include stimulants, cannabinoids, hallucinogens, and depressants (21). 
According to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 
the NPS market has grown exponentially from early reports of 150 analogs monitored in 
2010 to most recent statistics identifying over 670 NPS by the end of 2017 (22). The 
dominating trend that synthetic cannabinoids and stimulants, most notably synthetic 
cathinones or “bath salts”, continues to account for nearly 80% of all confiscated NPS (22, 
23). These new compounds pose a greater threat to the public health in comparison to 
known controlled substances due to an overall lack of information and inadequate 
resources for detecting the wide range of unknown analogs. (24). Without clear evidence 
of the psychoactive properties of the drug, potential for abuse, or absence of any medicinal 
properties, it may be difficult to include the NPS into the list of controlled substances.  
 
1.3.2 Wide Spread Internet Availability 
Serious health and safety concerns grow with the rapid and continuous emergence of 
NPS that have not yet been scheduled. Recent success and prevalence of the NPS 
phenomenon have largely been instigated by the convenience of online markets and 
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widespread availability of product on the Internet (25). Online forums offer consumers an 
uncensored space to discuss the drug efficacy and to relate with others on post-
hallucinogenic experiences with some degree of anonymity (24). Clandestine laboratories 
produced SC for online marketing by spraying these compounds onto dried plant material 
that appear similar to cannabis and attractively packaging them to sell online. These SC 
packets were often labeled as “herbal incense”, “spice” or “K2” which are not suitable for 
human consumption (26). It has been increasingly difficult for law enforcement and 
forensic scientists to keep up with the ease of purchase and misconstrued perceptions that 
NPS are relatively safe. 
 
1.3.3 Limited References and Structural Similarities 
Forensic toxicologists tend to only encounter NPS in intoxication or postmortem 
cases; however, this does not exactly equate to the true amount of people that consume 
these dangerous substances. In addition to the increasing number of different NPS, the 
extensive metabolism of synthetic cannabinoids is problematic for the detection of the 
analytes by standard urine drug screening tests (24, 26). Routine forensic laboratories may 
not have the necessary resources, analytical techniques or instrumentation to detect certain 
NPS. Reliable identification and quantification of newly reported NPS and their 
metabolites require certified reference standards for confirmatory testing. Lack of reference 
materials due to the novelty of these compounds may require upwards of a year to fully 
commercialize the production. The expensive and time-consuming research and 
development process does not seem to be economically viable as modified variations of 
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the drug are sold on online markets prior to the reference material even becoming available 
(27). Similar structures also may appear to have near-identical mass fragmentation patterns, 
making it rather tough to decipher between close analogs.  
 
1.3.4 Storage Conditions 
Large quantity of case submissions, difficulty of NPS identification, and long 
analysis times are some examples of the many factors that contribute to casework backlogs 
in forensic toxicology laboratories (28). Due to frequent delays and varying time intervals 
between sample collection and drug quantitation, further research into analyte stability over 
long time periods is of increasing significance. Analysis can often be delayed for several 
months to over a year, potentially resulting in significantly lower concentrations or a 
complete absence of any drug present. Sample degradation in biological matrices often 
occur as a result of enzymatic metabolism, heat or chemical decomposition, or suboptimal 
storage conditions (29). Although the addition of preservatives and anticoagulants as well 
as specimen storage under freezing conditions at around -20ºC can delay this concentration 
decrease, it does not fully prevent the degradation. Examples of common preservatives 
include sodium fluoride, potassium oxalate or ethylenediaminetetraacetic acid (EDTA). 
The type of sample container can also affect the analyte concentration as the drug binds to 
the plastic or glass tube (29). Short-term stability results reveal that freezing evidence 
samples upon receipt by law enforcement is the most clear and effective measure to prevent 
degradation of synthetic cannabinoids in biological specimens (3). However, there is 
currently a lack of knowledge over the long-term stability of many synthetic cannabinoids.  
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1.4 Research Objective 
Synthetic cannabinoids, similar to other emerging novel psychoactive substances, 
have been increasing in their rates of drug abuse and deaths due to drug overdose. A 
validated method is necessary to detect and accurately quantify synthetic cannabinoids in 
biological matrices such as blood and urine. More significantly, the lack of reference 
materials and rapidly changing structures have made it extremely difficult to research the 
stability of synthetic cannabinoids. In addition to the validation of the methods developed 
according to the Academy Standards Board (ASB) guidelines, previously drafted by the 
Scientific Working Group for Forensic Toxicologists (SWGTOX), an investigation on the 
stability of synthetic cannabinoids is essential for monitoring analyte degradation in 
biological samples (30, 31). The research will be important for routine forensic casework 
as well as maintaining a safe environment and health of public communities. 
The objective of this research was to assess the stability and amount of degradation 
over time of select 17 synthetic cannabinoids in human whole blood and 10 metabolites in 
urine. Synthetic cannabinoids include 4-cyano CUMYL-BUTINACA, ADB-PINACA, 
EMB-FUBINACA, JWH-250, MO-CHMINACA, 5-fluoro-3,5-ABPFUPPYCA, 5-fluoro 
ADB-PINACA, APP-PICA, CUMYL-THPINACA, PB-22, XLR11, 5-fluoro PY-
PINACA, MDMB-FUBICA, MEP-CHMICA, NM2201, RCS-8, and UR144. Metabolites 
in the urine stability analysis include 5-fluoro MDMB-PICA metabolite 7, 5-fluoro PB-22 
3-carboxyindole, AB-FUBINACA metabolite 3, ADB-PINACA N-(4-hydroxypentyl), 
ADB-PINACA pentanoic acid, UR-144 Degradant N-pentanoic acid, PB-22 N-(5-
hydroxypentyl), MDMB-FUBICA metabolite 3, UR-144 N-(5-hydroxypentyl), and JWH-
11 
250 N-pentanoic acid (See Figure 2 for specific metabolite structures). Analytes were 
separated into different mixes, aliquoted into individual storage containers as triplicate 
samples, and then stored separately at room temperature (20°C), refrigerator (4°C) and 
freezer (-20°C) for selected time periods. Quantitation of each synthetic cannabinoid was 
performed and the area ratio of the triplicates were averaged. Analytes were considered 
stable if the average area ratio between the analyte and internal standard at each select time 
point was within ±20% of the average area ratio response at 0 hour. Some synthetic 
cannabinoids were considered stable at specific timepoints if an overall stability data trend 
was observed despite the area ratio being outside the ±20% range. Three deuterated internal 
standards (ISTD) of UR144-d5, PB-22-d9, and XLR11-d5 were utilized for the analytes in 
blood. In addition to the previous three ISTDs, 5-fluoro PB-22 3-carboxyindole-d5 was 
used for the quantitation of each metabolite in urine. Quantitative analysis was performed 
using an Ultra-Fast Liquid Chromatography-Positive Electrospray Ionization-Tandem 
Mass Spectrometer (UFLC-ESI+/MS/MS) in order to obtain accurate and precise results.  
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Figure 1: Chemical Structures for Blood Analysis. (A) Synthetic Cannabinoid Analytes 
(32). (B) Deuterated Internal Standards (32). 
(A)
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MDMB-FUBICA 
 
MEP-CHMICA 
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Figure 2: Chemical Structures for Urine Analysis. (C) Synthetic Cannabinoid 
Metabolites (32). (D) Deuterated Internal Standards (32). See Table 1 for the list of full 
chemical names for each metabolite. 
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Table 1: Full Chemical Names of the Urine Metabolites from Cayman Chemical. 
Synthetic Cannabinoids Formal Chemical Name 
5-fluoro MDMB-PICA 
metabolite 7 
(S)-2-(1-(5-fluoropentyl)-1H-indole-3-
carboxamido)-3,3-dimethylbutanoic acid 
5-fluoro PB-22  
3-carboxyindole 
1-(5-fluoropentyl)-1H-indole-3-carboxylic acid 
AB-FUBINACA metabolite 3 
N-[[1-[(4-fluorophenyl)methyl]-1H-indazol-3-
yl]carbonyl]-L-valine 
ADB-PINACA  
N-(4-hydroxypentyl) 
N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-
hydroxypentyl)-1H-indazole-3-carboxamide 
ADB-PINACA pentanoic acid 
5-(3-((1-amino-3,3-dimethyl-1-oxobutan-2-
yl)carbamoyl)-1H-indazol-1-yl)pentanoic acid 
UR-144 Degradant  
N-pentanoic acid 
3-(3,3,4-trimethyl-1-oxo-4-penten-1-yl)-1H-
indole-1-pentanoic acid 
PB-22 N-(5-hydroxypentyl) 
quinolin-8-yl 1-(5-hydroxypentyl)-1H-indole-3-
carboxylate 
MDMB-FUBICA metabolite 3 
(S)-2-(1-(4-fluorobenzyl)-1H-indole-3-
carboxamido)-3,3-dimethylbutanoic acid 
UR-144 N-(5-hydroxypentyl) 
[1-(5-hydroxypentyl)-1H-indol-3-yl](2,2,3,3-
tetramethylcyclopropyl)-methanone 
JWH-250 N-pentanoic acid 
5-(3-(2-(2-methoxyphenyl)acetyl)-1H-indol-1-
yl)pentanoic acid 
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2. MATERIALS AND METHODS 
2.1 Theory of Instrumentation 
2.1.1 Liquid Chromatography 
 Liquid Chromatography (LC) is a widely utilized, analytical separation technique 
that introduces a sample to a column packed with an adsorbent material, more commonly 
known as the stationary phase. Liquid mobile phase is continuously flushed through the 
column at high pressure in order to move the analyte through the stationary phase. As 
different sample interactions occur with both the stationary phase and mobile phase, 
individual chemical components in the sample will be separated based on their polarity, 
electrical charge, molecular size, or affinity to the column (33). A nonpolar, organic 
solvent, such as hexane, is typically utilized in normal-phase chromatography as opposed 
to more polar mobile phases, like water, are used for reverse-phase chromatography. 
Analytical columns are typically coated with silica and designed with different modified 
chemical compositions, particle sizes, affinity types, and column sizes. Molecules with a 
stronger affinity to the stationary phase will adhere to the adsorbent material as other 
sample components with weaker affinity will pass more quickly (33). For example, in 
reverse-phase chromatography, a nonpolar molecule will tend to interact more strongly to 
a nonpolar stationary phase, such as the hydrophobic particle chemistry found in a C18 
column, than that of a polar molecule; thereby polar analytes will elute before the nonpolar 
molecules. Normal-phase chromatography acts opposite to that of reverse-phase 
chromatography in which nonpolar analytes will elute first as polar molecules adhere to 
the polar silica media found in the analytical column. The goal for any given sample 
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involved with LC is to have complete separation of all sample components prior to 
detection, thus selecting the appropriate stationary phase and mobile phase are both 
important. 
 Mobile phase compositions are optimized in order for a LC method to properly 
separate the sample components for drug identification and quantitation. Mobile phase 
gradients are designed such that the analyte adhering to the column will eventually partition 
into the mobile phase and move along the column for detection (34). Column retention of 
the compound allows enough time for unwanted components to first pass through the 
column before eluting the analyte of interest. Water, acetonitrile, methanol, formic acid 
and buffer solutions are examples of mobile phases typically used on a LC system.  
High-performance liquid chromatography (HPLC) and ultra-performance liquid 
chromatography (UPLC) are examples of analytical instrumentation that can be used in 
forensics for better identification and quantification of drugs (35). UPLC offers significant 
advances for liquid chromatography analysis in better separation power, enhanced mass 
resolution, faster run times, and higher sensitivity. 
 
2.1.2 Electrospray Ionization 
 Atmospheric pressure ionization (API) methods are useful for volatizing and 
ionizing compounds for mass spectrometric analysis. The two most popular API interfaces 
include atmospheric pressure chemical ionization (APCI) and electrospray ionization 
(ESI). Although APCI is widely utilized for MS analysis, ESI has been increasing in 
acceptance within the forensic community since it can analyze a wider range of samples 
17 
and determine the molecular mass of compounds a lot easier. ESI is the softest ionization 
technique available generating ions for compounds that are highly polar, nonvolatile or 
thermally unstable (36). ESI sources consist of two main components: a capillary tube that 
applies high voltages to the sample solution and a counter electrode that creates an 
electrical field.  Electrospray ionization begins with the nebulization of the sample solution 
into a fine mist of electrically charged droplets through a capillary tube by applying a high 
electric field and a nebulizing gas, such as nitrogen. As the solvent begins to evaporate, the 
charged droplets will continuously reduce in size. Ions will then be liberated from the 
droplets once the electrostatic repulsion between the charges is stronger than the surface 
tension of the liquid. Ejected ions are ultimately transported from the ESI source into the 
vacuum and mass analyzer of the mass spectrometer (37, 38).  
 
2.1.3 Tandem Mass Spectrometry 
 Mass Spectrometry (MS) is a powerful analytical instrument that can provide both 
qualitative and quantitative analyte data. This sensitive and specific technique is typically 
comprised of four major components: an ion source that ionizes the sample molecules, a 
mass analyzer that filters ions based on their mass-to-charge (m/z) ratios, an ion detector 
that measures the ion amount in the form of an electrical signal, and a recording device that 
coverts the electrical signal to a chromatogram (39). Mass spectrometers are often coupled 
to either a LC or gas chromatograph (GC) system for better separation prior to detection. 
In the context of forensics, MS instruments can be utilized for a variety of evidence types 
including toxicological samples, controlled substances, fire debris and trace evidence.  
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 Tandem mass spectrometers (MS/MS) break down precursor ions into product ions 
for detection. A common instrument used for MS/MS is a Triple Quadrupole Mass 
Spectrometer (QQQ) which consists of three quadrupoles in sequence where the first and 
third quadrupoles serve as mass analyzers, and the second quadrupole is a collision cell for 
fragmentation (40). As the voltage of the rods change, the first quadrupole (Q1) starts by 
filtering the precursor ions by size towards the collision cell. In the second quadrupole 
(Q2), ions will interact and fragment by collision with inert gas under high pressure to form 
product ions. Fragmented ions will be filtered by their m/z ratios in the second mass 
analyzer or third quadrupole (Q3) before passing the detector (41). MS/MS is useful for 
structural determination and is capable of distinguishing co-eluting ions with identical 
exact mass through their unique fragmentation patterns (42).  Other examples of MS/MS 
instruments include the Triple Quadrupole Linear Ion Trap (QTRAP) and Quadrupole 
Time of Flight (QTOF) mass spectrometers. The QTRAP system functions similar to the 
QQQ as previously described with exception of the third quadrupole in which ions are 
accumulated for a few milliseconds prior to scanning. The linear ion trap thereby allows 
higher sensitivity for identification and quantification of the fragment ions (43). 
 
2.2 Materials 
2.2.1 Standards and Reagents 
 Certified drug-free human whole blood was purchased from the Boston Medical 
Center (Boston, MA, USA) and Biological Specialty Corporation (Colmar, PA). Urine 
donations were received at the Boston University School of Medicine (Boston, MA, USA) 
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following the approved Institutional Review Board protocol and screened for the absence 
of chemicals and drugs using an Agilent 7890A Gas Chromatography–Mass Spectrometer 
(GC/MS, Santa Clara, CA, USA). All twenty-seven cannabinoid certified reference 
standards and four deuterated internal standards used in this research were purchased 
through Cayman Chemical Company (Ann Arbor, MI, USA) as represented in Table 2 and 
3. The following reagents were purchased from Fisher Scientific (Waltham, MA, USA): 
optima grade methanol, optima grade acetonitrile, optima grade formic acid, ethyl acetate, 
ammonium acetate, ACS grade sodium fluoride, and concentrated hydrochloric acid. Fresh 
millipore deionized water (DI H2O) was obtained from the Synergy UV-R water 
purification system (EMD Millipore, Darmstadt, Germany). An Oakton 700 Ion Benchtop 
pH meter (Fisher Scientific, Waltham, MA, USA) was utilized for reagent preparation. For 
sample preparation, supported-liquid extraction was performed using Biotage ISOLUTE 
SLE+ 1 mL cartridges (Charlotte, NC, USA). 
Table 2: Lot numbers of certified reference materials for blood stability analysis.  
All certified reference standards were stored in freezer at -20°C. 
Product Formulation Size Lot Numbers 
4-cyano CUMYL-BUTINACA 1 mg solid 0490444-17 
ADB-PINACA 1 mg/mL MeOH 0468161 
EMB-FUBINACA 1 mg solid 0473498-25 
JWH-250 1 mg/mL MeOH 0509389-1 
MO-CHMINACA 1 mg solid 0465397-25 
5-fluoro-3,5-AB-PFUPPYCA 1 mg solid 0472185-17 
5-fluoro ADB-PINACA 1 mg solid 0485273-10 
APP-PICA 1 mg solid 0470126-13 
CUMYL-THPINACA 1 mg solid 0467623-26 
PB-22 1 mg/mL ACN 0471823 
XLR11 1 mg/mL MeOH 0498175-1 
5-fluoro PY-PINACA 1 mg/mL MeOH 0487129 
MDMB-FUBICA 1 mg solid 0488504-12 
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MEP-CHMICA 1 mg solid 0506714-4 
NM2201 1 mg/100µL ACN 0464900-37 
RCS-8 1 mg/mL MeOH 0491176-1 
UR144 1 mg/mL MeOH 0498308 
UR144-d5 1 mg/mL MeOH 0516864-1 
PB-22-d9 1 mg/mL ACN 0516372-1 
XLR11-d5 1 mg/mL MeOH 0514591-1 
 
 
Table 3: Lot numbers of certified reference materials for urine stability analysis.  
All certified reference standards were stored in freezer at -20°C.  
 
Product Formulation Size Lot Numbers 
5-fluoro MDMB-PICA metabolite 7 1 mg solid 0504649-2 
5-fluoro PB-22 3-carboxyindole 1 mg solid 0479732-16 
AB-FUBINACA metabolite 3 1 mg solid 0491112-9 
ADB-PINACA N-(4-hydroxypentyl) 1 mg solid 0453157-16 
ADB-PINACA pentanoic acid 1 mg solid 0506717-2 
UR-144 Degradant N-pentanoic acid 1 mg/100µL MeOH 0448728-16 
PB-22 N-(5-hydroxypentyl) 1 mg solid 0457378-14 
MDMB-FUBICA metabolite 3 1 mg solid 0490397-5 
UR-144 N-(5-hydroxypentyl) 500 µg solid 0475198-3 
JWH-250 N-pentanoic acid 1 mg solid 0430527-49 
5-fluoro PB-22 3-carboxyindole-d5 100 µg/mL ACN 0471690 
 
2.2.2 UFLC-ESI-MS/MS 
 Quantification of the synthetic cannabinoid compounds was completed using 
Shimadzu Prominence Ultra-Fast Liquid Chromatograph (UFLC) equipped with two LC-
20AD model pumps and a SIL-20AC model autosampler (Shimadzu, Kyoto, Japan). 
Chromatographic separation was achieved using a Waters XBridge C18 3.5µM, 2.1 mm x 
50 mm ID column (Waters, Milford, MA, USA). Detection of all analytes was performed 
on a SCIEX 4000 Q-Trap Tandem Mass Spectrometer (ESI+/MS/MS) with a Turbo V 
electrospray ionization source in positive mode (Framingham, MA, USA). Results were 
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collected using Analyst™ (version 1.6.2) software and analyzed with MultiQuant™ 3.0 
(version 3.0.5373.0) software (SCIEX).  
 
2.3 Methods 
2.3.1 LC-MS/MS Method Parameters 
 The method development and validation for the quantification of the different 
synthetic cannabinoids utilized in this stability evaluation was researched by Daniel Lee 
and Cassandra Swart (44, 45). The compound and source optimization processes for blood 
were developed by Daniel Lee and similarly for urine by Cassandra Swart. Each analyte 
and internal standard were assessed to determine the top two product ions (Q3) that 
exhibited the highest intensity. In Table 4 and Table 5, the multiple reaction monitoring 
(MRM) optimization of each analyte shows the precursor ion (Q1), top two product ions 
(Q3), declustering potential (DP), collision energy (CE), and cell exit potential (CXP) for 
blood and urine respectively. Analytes labeled with a “1” were the most intense fragment 
ions utilized for quantification; whereas those denoted by “2” were the second highest 
intensity fragment ions used for qualification or confirmation of that specific analyte. The 
MRM scans were conducted in positive ionization mode for a total run of 8.0 minutes.  
 
Table 4: Multiple Reaction Monitoring (MRM) Table for blood stability analytes. 
Analyte Q1 (Da) Q3 (Da) DP (V) CE (V) CXP (V) 
4-cyano CUMYL-BUTINACA 1 361.2 226.2 62.00 29.71 39.59 
4-cyano CUMYL-BUTINACA 2 361.2 119.2 62.00 33.31 19.95 
ADB-PINACA 1 345.2 328.3 13.33 13.33 19.05 
ADB-PINACA 2 345.2 215.3 35.06 35.06 36.79 
EMB-FUBINACA 1 398.2 324.3 72.00 21.90 18.20 
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EMB-FUBINACA 2 398.2 109.2 72.00 57.14 18.16 
JWH-250 1 336.3 121.2 87.00 28.83 20.52 
JWH-250 2 336.3 91.2 87.00 65.18 15.21 
MO-CHMINACA 1 387.3 241.3 70.00 22.71 41.62 
MO-CHMINACA 2 387.3 145.2 70.00 49.53 24.59 
5-fluoro-3,5-AB-PFUPPYCA 1 393.0 189.2 100.00 52.63 32.75 
5-fluoro-3,5-AB-PFUPPYCA 2 393.0 134.2 100.00 89.11 22.80 
5-fluoro ADB-PINACA 1 363.0 346.3 56.00 14.14 9.91 
5-fluoro ADB-PINACA 2 363.0 233.2 56.00 35.06 38.99 
APP-PICA 1 378.2 361.3 56.00 14.12 10.83 
APP-PICA 2 378.2 214.3 56.00 26.66 36.84 
CUMYL-THPINACA 1 378.2 260.2 65.00 16.02 14.52 
CUMYL-THPINACA 2 378.2 243.3 65.00 28.76 43.91 
PB-22 1 359.2 214.3 53.00 18.04 36.93 
PB-22 2 359.2 144.2 53.00 50.99 24.63 
XLR11 1 330.3 232.3 95.00 33.95 39.08 
XLR11 2 330.3 125.3 95.00 33.03 22.65 
5-fluoro PY-PINACA 1 304.3 233.3 78.00 27.50 39.70 
5-fluoro PY-PINACA 2 304.3 145.1 78.00 50.80 24.16 
MDMB-FUBICA 1 397.2 252.3 61.00 21.03 43.99 
MDMB-FUBICA 2 397.2 109.2 61.00 52.42 18.53 
MEP-CHMICA 1 371.3 240.4 60.00 20.80 39.96 
MEP-CHMICA 2 371.3 55.3 60.00 82.38 7.68 
NM2201 1 376.2 232.3 55.00 15.34 41.02 
NM2201 2 376.2 144.3 55.00 52.16 23.53 
RCS-8 1 376.2 121.3 104.00 32.85 20.22 
RCS-8 2 376.2 91.2 104.00 74.63 15.05 
UR144 1 312.3 214.3 97.00 32.57 37.00 
UR144 2 312.3 125.1 97.00 31.85 21.96 
UR144-d5 ISTD 1 317.3 125.2 94.00 32.30 21.78 
UR144-d5 ISTD 2 317.3 55.2 125.00 53.00 10.00 
PB-22-d9 ISTD 1 368.2 223.3 58.00 18.70 37.24 
PB-22-d9 ISTD 2 368.2 145.2 58.00 53.31 24.59 
XLR11-d5 ISTD 1 335.2 125.3 95.00 34.43 21.79 
XLR11-d5 ISTD 2 335.2 55.2 95.00 66.65 8.23 
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Table 5: Multiple Reaction Monitoring (MRM) Table for urine stability metabolites. 
Analyte Q1 (Da) Q3 (Da) DP (V) CE (V) CXP (V) 
5-fluoro MDMB-PICA metabolite 7 1 363.2 232.2 66.00 20.27 42.05 
5-fluoro MDMB-PICA metabolite 7 2 363.2 144.2 66.00 54.52 24.65 
5-fluoro PB-22 3-carboxyindole 1 250.2 206.3 75.00 22.03 35.20 
5-fluoro PB-22 3-carboxyindole 2 250.2 118.1 75.00 33.19 20.14 
AB-FUBINACA metabolite 3 1 370.2 324.3 72.00 19.48 26.22 
AB-FUBINACA metabolite 3 2 370.2 253.1 72.00 28.78 44.56 
ADB-PINACA N-(4-hydroxypentyl) 1 361.3 344.4 51.00 14.80 20.21 
ADB-PINACA N-(4-hydroxypentyl) 2 361.3 316.4 51.00 22.21 17.09 
ADB-PINACA pentanoic acid 1 375.2 358.3 62.00 14.61 19.89 
ADB-PINACA pentanoic acid 2 375.2 330.3 62.00 22.27 18.61 
UR-144 Degradant N-pentanoic acid 1 342.3 244.2 75.00 32.14 43.87 
UR-144 Degradant N-pentanoic acid 2 342.3 55.3 75.00 73.77 7.55 
PB-22 N-(5-hydroxypentyl) 1 375.2 230.3 55.00 19.84 41.12 
PB-22 N-(5-hydroxypentyl) 2 375.2 144.2 55.00 50.44 28.08 
MDMB-FUBICA metabolite 3 1 383.2 252.2 66.00 19.57 44.45 
MDMB-FUBICA metabolite 3 2 383.2 83.2 66.00 120.68 12.40 
UR-144 N-(5-hydroxypentyl) 1 328.3 125.3 85.00 38.05 21.71 
UR-144 N-(5-hydroxypentyl) 2 328.3 55.3 85.00 61.70 8.11 
JWH-250 N-pentanoic acid 1 366.2 121.2 86.00 32.28 20.18 
JWH-250 N-pentanoic acid 2 366.2 91.2 86.00 69.59 15.11 
5-F PB-22 3-carboxyindole-d5 ISTD 1 255.2 211.3 72.00 22.64 37.60 
5-F PB-22 3-carboxyindole-d5 ISTD 2 255.2 123.2 72.00 34.45 21.56 
UR144-d5 ISTD 1 317.3 125.2 94.00 32.30 21.78 
UR144-d5 ISTD 2 317.3 55.2 125.00 60.97 8.76 
PB-22-d9 ISTD 1 368.2 223.3 58.00 18.70 37.24 
PB-22-d9 ISTD 2 368.2 145.2 58.00 53.31 24.59 
XLR11-d5 ISTD 1 335.2 125.3 95.00 32.30 21.78 
XLR11-d5 ISTD 2 335.2 55.2 95.00 60.97 8.76 
  
Furthermore, the optimized ion source and gas parameters used in this research are 
listed in Table 6. The LC method utilizes two mobile phases: 0.1% formic acid in millipore 
H2O (Mobile Phase A) and 0.1% formic acid in optima grade acetonitrile (Mobile Phase 
B). The method has a starting condition of 5% mobile phase B with a flow rate set to 0.6 
mL/min and a 10 µL injection volume. Both LC pumps have maximum pressure of 5000 
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psi equipped with a binary flow pumping mode. Pre-equilibration of the LC system for 
1.50 minutes allows the instrument to reach the method starting conditions prior to each 
run, such as the oven temperature and pump pressure. For each 8-minute analysis run, a 
gradient flow in the percentage of mobile phase B changes over time between 5% to 95%. 
After the run is complete, re-equilibration of the system occurs from 8.00 to 9.00 minutes. 
In Table 8, the autosampler settings shown are optimized in order to minimize carryover 
or cross-contamination between each sample injection (46).   
Table 6: Ion Source and Gas Parameters. 
Curtain Gas Collision Gas Ion Spray Voltage Temp Ion Source Gas 1 Ion Source Gas 2 
25.0 psi High 2500 V 550°C 45.0 psi 45.0 psi 
 
 
Table 7: LC Time Program. 
 
Time (min) Module Event Parameter (%) 
0.01 Pumps Pump B Concentration 5 
0.50 Pumps Pump B Concentration 5 
5.50 Pumps Pump B Concentration 95 
7.50 Pumps Pump B Concentration 95 
8.00 Pumps Pump B Concentration 5 
9.00 Controller Stop  
 
Table 8: Auto Sampler Settings. 
Rinsing 
Volume 
Needle 
Stroke 
Rinsing 
Speed 
Sampling 
Speed 
Purge 
Time 
Rinse Dip 
Time 
Cooler 
Temp 
1000 µL 52 mm 35 µL/sec 3.0 µL/sec 25.0 min 5 sec 15 °C 
 
2.3.2 Preparation of Stored Samples 
 For the preparation of the long-term stability stored samples, all cannabinoid 
standards purchased from Cayman Chemical were individually prepared at a concentration 
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of 1 mg/mL by dissolving the 1 mg solid in either 1 mL of optima grade MeOH or 1 mL 
of optima grade ACN except for NM2201 which was prepared by the manufacturer as 1 
mg/100 µL. The NM2201 standard was prepared at a 1 mg/mL concentration with the 
addition of 900 µL of ACN. Each solution was vortexed for 30 seconds. As shown in Table 
9, the seventeen analytes were divided in three different mixes. For each mix of five or six 
cannabinoid analytes, a serial dilution was performed to make three 5 µg/mL stock 
solutions (B MIX 1-3) in 5 mL of ACN from the 1 mg/mL or 100 µg/mL standard solutions. 
In six individual 500 mL volumetric flasks, 500 mL of whole blood is added to each flask 
for a total of 3.0 liters of blood. Using the stock solutions (B MIX 1-3), each of the 500 mL 
volumetric flasks were spiked with 150 µL for low concentration or 1.0 mL for high 
concentration of the designated mix detailed in Table 9. Each volumetric flask was mixed 
for 30 minutes and poured into individual 1000 mL beakers. Using a repeater pipette, 5 mL 
of the blood mixes (B LOW 1-3 and B HIGH 1-3) were aliquoted in triplicates to 6 mL BD 
Vacutainer Plastic Collection Tubes (Fisher Scientific, Waltham, MA, USA) for storage. 
Temperatures for the room, refrigerator and freezer samples were recorded at the following 
time points for analysis: 0-hour, 24-hour, 72-hour, 1 week, 3 weeks, 5 weeks, 9 weeks, 17 
weeks, 21 weeks, and 35 weeks. These timepoints were used for the nonpreserved blood 
and the blood preserved with sodium fluoride and included all analytes in blood. No 
internal standards were added into any of the samples at Day 0. This complete procedure 
was repeated two times: one for blood with sodium fluoride preservatives and another for 
blood without preservatives. 
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Table 9: Preparation of Long-Term Stored Samples for Low and High Concentration 
Blood Mixes. 
Mix 1 consists of the first five synthetic cannabinoids. Mix 2 is the middle following six 
analytes. Mix 3 is the last six synthetic cannabinoid analytes. 
 
Blood Mixes Initial Conc. WS Volume Final Volume Final Conc. 
4-cyano CUMYL-BUTINACA 
B MIX 1 
5 µg/mL 
150 µL 
500 mL 
Blood 
B LOW 1 
1.5 ng/mL 
ADB-PINACA 
EMB-FUBINACA 
JWH-250 
1.0 mL 
500 mL 
Blood 
B HIGH 1 
10 ng/mL MO-CHMINACA 
5-fluoro-3,5-AB-PFUPPYCA 
B MIX 2 
5 µg/mL 
150 µL 
500 mL 
Blood 
B LOW 2 
1.5 ng/mL 
5-fluoro ADB-PINACA 
APP-PICA 
CUMYL-THPINACA 
1.0 mL 
500 mL 
Blood 
B HIGH 2 
10 ng/mL 
PB-22 
XLR11 
5-fluoro PY-PINACA 
B MIX 3 
5 µg/mL 
150 µL 
500 mL 
Blood 
B LOW 3 
1.5 ng/mL 
MDMB-FUBICA 
MEP-CHMICA 
NM2201 
1.0 mL 
500 mL 
Blood 
B HIGH 3 
10 ng/mL 
RCS-8 
UR144 
 
Similar to the preparation of the long-term blood samples, the procedure was 
repeated for urine except for some minor differences. There were ten synthetic cannabinoid 
metabolites separated into three different mixes of three or four analytes. Serial dilutions 
yielded three 10 µg/mL stock solutions (U MIX 1-3) in 5 mL of ACN from the 1 mg/mL 
metabolite standards. To each 500 mL volumetric flask, the urine was spiked with 500 µL 
for low concentration and 1.25 mL for high concentration of the specified mix shown in 
Table 10. Individual samples were aliquoted in triplicates to 15 mL Falcon Conical 
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Centrifuge Tubes (Fisher Scientific, Waltham, MA, USA) and stored in the same room 
temperature, refrigerator and freezer conditions as the blood samples. 
 
Table 10: Preparation of Long-Term Stored Samples for Low and High 
Concentration Urine Mixes.  
Mix 1 consists of the first four synthetic cannabinoid metabolites. Mix 2 is the middle 
following three metabolites. Mix 3 is the last three synthetic cannabinoid metabolites. 
 
Urine Mixes Initial Conc. WS Volume Final Volume Final Conc. 
5-fluoro MDMB-PICA metabolite 7 
U MIX 1 
10 µg/mL 
500 µL 
500 mL 
Urine 
U LOW 1 
10 ng/mL 5-fluoro PB-22 3-carboxyindole 
AB-FUBINACA metabolite 3 
1.25 mL 
500 mL 
Urine 
U HIGH 1 
25 ng/mL ADB-PINACA N-(4-hydroxypentyl) 
ADB-PINACA pentanoic acid 
U MIX 2 
10 µg/mL 
500 µL 
500 mL 
Urine 
U LOW 2 
10 ng/mL UR-144 Degradant N-pentanoic acid 
PB-22 N-(5-hydroxypentyl) 
1.25 mL 
500 mL 
Urine 
U HIGH 2 
25 ng/mL  
MDMB-FUBICA metabolite 3 
U MIX 3 
10 µg/mL 
500 µL 
500 mL 
Urine 
U LOW 3 
10 ng/mL UR-144 N-(5-hydroxypentyl) 
JWH-250 N-pentanoic acid 
1.25 mL 
500 mL 
Urine 
U HIGH 3 
25 ng/mL  
 
 All short-term stability samples only included high concentration level while those 
in the long-term stability included a low and high concentration. For the preparation of the 
short-term stability stored samples, the 1 mg/mL synthetic cannabinoid standards from 
Cayman Chemical were vortexed for 30 seconds prior to use. As shown in Table 11, a 
serial dilution was performed to make a 5 µg/mL stock solution (B MIX 4) in 4 mL of 
ACN from the 1 mg/mL standards. In a 100 mL volumetric flask, 200 µL of the 5 µg/mL 
stock solution (B MIX 4) is spiked into 100 mL of whole blood with EDTA. The volumetric 
flask was mixed for 30 minutes, and the blood was poured into a 100 mL beaker. Using a 
repeater pipette, 2.5 mL of the blood mix (B HIGH 4) was aliquoted in triplicates to 6 mL 
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BD Vacutainer Plastic Collection Tubes (Fisher Scientific, Waltham, MA, USA) for 
storage under room temperature, refrigeration and freezer. Analysis was performed for the 
following time points: 0-hour, 24-hour, 72-hour, 1 week, and 3 weeks. No internal 
standards were added into any of the samples at Day 0. Only a subset of synthetic 
cannabinoids was evaluated in blood with EDTA (Table 11).  
 
Table 11: Preparation of Short-Term Stored Samples for High Concentration Blood 
with EDTA Mix. 
 
Blood Mix Initial Conc. WS Volume Final Volume Final Conc. 
5-fluoro ADB-PINACA 
B MIX 4 
5 µg/mL 
200 µL 
100 mL 
Blood 
B HIGH 4 
10 ng/mL 
APP-PICA 
CUMYL-THPINACA 
EMB-FUBINACA 
MEP-CHMICA 
NM2201 
XLR11 
 
Table 12: Preparation of Short-Term Stored Samples for High Concentration Blood 
without Preservatives Mix 3. 
 
Blood Mix Initial Conc. WS Volume Final Volume Final Conc. 
5-fluoro PY-PINACA 
B MIX 5 
5 µg/mL 
200 µL 
100 mL 
Blood 
B HIGH 5 
10 ng/mL 
MDMB-FUBICA 
MEP-CHMICA 
NM2201 
RCS-8 
UR144 
 
Similar to the short-term blood preserved with EDTA samples, 200 µL of the 5 
µg/mL stock solution (B MIX 5) was spiked into 100 mL of blood without preservatives 
as designated in Table 12. Individual samples were then aliquoted in triplicates to the 
plastic tubes and stored under the same time frame and storage conditions. Since there were 
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issues involved with the Mix 3 samples in the long-term stability for nonpreserved blood, 
a subset of synthetic cannabinoids shown in Table 12 were repeated for up to 3 weeks for 
stability analysis.  
Table 13: Preparation of Short-Term Stored Samples for High Concentration Urine 
with Sodium Fluoride Preservatives Mixes. 
 
Urine Mixes Initial Conc. WS Volume Final Volume Final Conc. 
5-fluoro MDMB-PICA metabolite 7 
U MIX 4 
5 µg/mL 
500 µL 
100 mL 
Urine 
U HIGH 4 
25 ng/mL 
5-fluoro PB-22 3-carboxyindole 
AB-FUBINACA metabolite 3 
ADB-PINACA N-(4-
hydroxypentyl) 
JWH-250 N-pentanoic acid 
ADB-PINACA pentanoic acid 
U MIX 5 
5 µg/mL 
500 µL 
100 mL 
Urine 
U HIGH 5 
25 ng/mL 
UR-144 Degradant N-pentanoic 
acid 
PB-22 N-(5-hydroxypentyl) 
MDMB-FUBICA metabolite 3 
 
 
 For the short-term stability samples of urine with sodium fluoride preservatives, the 
nine synthetic cannabinoid metabolites were divided in two different mixes according to 
Table 13. For each mix of four or five SC analytes, a serial dilution was performed to make 
two 5 µg/mL stock solutions (U MIX 4-5) in 4 mL of ACN from the 1 mg/mL or 100 
µg/mL standard solutions. In two individual 100 mL volumetric flasks, 5.0 grams of 
sodium fluoride and 100 mL of urine were added to each flask. Using the stock solutions 
(U MIX 4-5), 500 µL is spiked into each respective 100 mL of urine preserved with 1% 
sodium fluoride. Each volumetric flask was mixed for 30 minutes and poured into a 100 
mL beaker. With a repeater pipette, 2.5 mL of the urine mixes (U HIGH 4-5) were aliquoted 
in triplicates to 15 mL Falcon Conical Centrifuge Tubes (Fisher Scientific, Waltham, MA, 
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USA). The samples were stored under the same storage conditions as the short-term blood 
samples for a 3-week duration. 
 
2.3.3 Preparation of Calibrators 
  For the preparation of the calibrators in blood, a 10 µg/mL Stock 1 solution (S1) 
in 4 mL of ACN was prepared using all seventeen 1 mg/mL or 100 µg/mL solutions of the 
synthetic cannabinoid standards purchased from Cayman Chemical. Stock 1 solution was 
further diluted to make a 1 µg/mL Stock 2 solution (S2) in 4 mL of ACN. Another serial 
dilution of Stock 2 solution resulted in a 100 ng/mL Stock 3 solution (S3) in 4 mL of ACN. 
As shown by Table 14, the three stock solutions (S1-S3) are further diluted to create the 
working stock solutions of the eight calibration points (WS1-8), low (WS LOW), middle 
(WS MID) and high (WS HIGH) quality controls (QC). An internal standard stock solution 
(ISTD S1) was prepared at the concentration of 10 µg/mL in 2 mL of ACN by combining 
UR144-d5, PB-22-d9, and XLR11-d5. A serial dilution of ISTD S1 is conducted to make 
a 225 ng/mL internal standard working stock solution (ISTD S2) in 20 mL of ACN. 
Calibrators in blood generally ranged from 0.5 ng/mL to 25 ng/mL except for NM2201 and 
APP-PICA had a working range of 0.1 ng/mL to 25 ng/mL and MO-CHMINACA ranged 
from 0.5 ng/mL to 15 ng/mL. Additionally, a low QC, mid QC and high QC samples were 
made at 1 ng/mL, 7 or 10 ng/mL, and 20 ng/mL respectively. At each time point, a new 
calibration curve was prepared in 15 mL glass test tubes consisting of 300 µL of certified 
drug-free human whole blood, 20 µL of the specified working stock solution (WS 1-8, WS 
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LOW, WS MID, WS HIGH) in Table 14, and 10 µL of ISTD S2. No working stock or 
ISTD solutions were added to the double blank samples.  
 
Table 14: Preparation of Working Stock Solutions for Blood Stability Calibrators. 
Spike Conc. is the final concentration of the calibration curve points and quality controls 
after 20 µL of the working stock (WS) solutions are spiked in 300 µL of whole blood.  
 
Stock Initial Conc. Stock Volume Final Volume WS Conc. WS Name Spike Conc. 
S3 100 ng/mL 
30 µL 2 mL ACN 1.5 ng/mL WS1 0.1 ng/mL 
150 µL 2 mL ACN 7.5 ng/mL WS2 0.5 ng/mL 
300 µL 2 mL ACN 15 ng/mL WS LOW 1 ng/mL 
S2 1 µg/mL 
30 µL 2 mL ACN 15 ng/mL WS3 1 ng/mL 
60 µL 2 mL ACN 30 ng/mL WS4 2 ng/mL 
150 µL 2 mL ACN 75 ng/mL WS5 5 ng/mL 
210 µL 2 mL ACN 105 ng/mL WS MID 7 ng/mL 
300 µL 2 mL ACN 150 ng/mL WS MID 10 ng/mL 
S1 10 µg/mL 
30 µL 2 mL ACN 150 ng/mL WS6 10 ng/mL 
45 µL 2 mL ACN 225 ng/mL WS7 15 ng/mL 
60 µL 2 mL ACN 300 ng/mL WS HIGH 20 ng/mL 
75 µL 2 mL ACN 375 ng/mL WS8 25 ng/mL 
 
For the calibrators in urine, serial dilutions of the ten 1 mg/mL metabolite standards 
were performed to yield both a 10 µg/mL Stock 4 solution (S4) and 1 µg/mL Stock 5 
solution (S5) in 4 mL of ACN. Working stock solutions of the eight calibration points 
(WS1-8) and quality controls (WS LOW, WS MID, and WS HIGH) were prepared from 
the two stock solutions (S4 and S5) following Table 15. Similar to the preparation of ISTD 
S2, another 225 ng/mL internal standard working stock solution (ISTD S3) in 10 mL ACN 
was made by combining 5-fluoro PB-22 3-carboxyindole-d5, UR144-d5, PB-22-d9 and, 
XLR11-d5. Calibrators in urine ranged from 5 ng/mL to 40 ng/mL with quality control 
samples at 5 ng/mL, 20 ng/mL, and 40 ng/mL. At each stability time point, a new 
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calibration curve was prepared with 300 µL of drug-free urine, 20 µL of the designated 
working stock solution (WS 1-8, WS LOW, WS MID, WS HIGH) in Table 15, and 10 µL 
of ISTD S3 in 15 mL glass test tubes. No working stock or ISTD solutions were added to 
the double blank samples. 
 
Table 15: Preparation of Working Stock Solutions for Urine Stability Calibrators. 
Spike Conc. is the final concentration of the calibration curve points and quality controls 
after 20 µL of the working stock (WS) solutions are spiked in 300 µL of urine. 
 
Stock Initial Conc. Stock Volume Final Volume WS Conc. WS Name Spike Conc. 
S5 1 µg/mL 
150 µL 2 mL ACN 75 ng/mL WS1 5 ng/mL 
150 µL 2 mL ACN 75 ng/mL WS LOW 5 ng/mL 
300 µL 2 mL ACN 150 ng/mL WS2 10 ng/mL 
450 µL 2 mL ACN 225 ng/mL WS3 15 ng/mL 
600 µL 2 mL ACN 300 ng/mL WS4 20 ng/mL 
600 µL 2 mL ACN 300 ng/mL WS MID 20 ng/mL 
S4 10 µg/mL 
75 µL 2 mL ACN 375 ng/mL WS5 25 ng/mL 
90 µL 2 mL ACN 450 ng/mL WS6 30 ng/mL 
105 µL 2 mL ACN 525 ng/mL WS7 35 ng/mL 
105 µL 2 mL ACN 525 ng/mL WS HIGH 40 ng/mL 
120 µL 2 mL ACN 600 ng/mL WS8 40 ng/mL 
  
Blood samples were prepared in 15 mL glass test tubes containing 300 µL of the 
stored blood sample and 10 µL of ISTD S2; whereas urine samples were prepared with 300 
µL of the stored urine sample and 10 µL of ISTD S3 solution. 
 
2.3.4 Supported-Liquid Extraction 
 Supported-liquid extraction (SLE) was performed on all samples in order to isolate 
the analytes of interest and remove undesired components in whole blood and urine prior 
to injection onto the LC system. Unlike solid-phase extraction (SPE) which requires 
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pretreatment steps for conditioning, equilibrating and washing the column, SLE reduces 
the overall extraction time with only two steps for loading and eluting (47, 48). All samples 
were first pretreated with 300 µL of ammonium acetate (50 mM, pH 4) and vortexed for 
30 seconds. Biotage ISOLUTE SLE+ 1 mL columns (Charlotte, NC, USA) were loaded 
onto a manifold rack with new 15 mL glass test tubes placed for elution. Pretreated samples 
were transferred into their respective SLE cartridges and slight pressure was added using a 
Silicone Bulb-Type Safety Pipet Filler (Fisher Scientific, Waltham, MA, USA). Samples 
were given five minutes to completely load onto the sorbent bed followed by adding 2.5 
mL of ethyl acetate for elution by gravity flow. After five minutes, an additional 2.5 mL of 
ethyl acetate was added. Remaining solvent in the SLE columns were blown out with the 
pipet filler after five minutes and placed onto the Organomation Multivap® Nitrogen 
Evaporator (Berlin, MA, USA) at 40°C for approximately 20 minutes.  
 After all samples were completely dried, they were reconstituted with 100 µL of 
50:50 solution of 0.1% formic acid in millipore H2O and 0.1% formic acid in ACN and 
transferred to LC vials with a flat-bottom liner. Samples were then analyzed by following 
the previously described LC-MS/MS method and pre-set conditions.  
 
2.3.5 Quantification of Analytes 
 Quantification of the synthetic cannabinoids in all samples was performed using 
LC-MS/MS to record the amount of degradation over time. The stability of the synthetic 
cannabinoids was evaluated by comparing the average area ratio of the analyte and ISTD 
at 0 hour to each time point for each storage condition. Since the samples were run in 
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triplicate, the average area ratio was calculated at that respective time point for samples 
stored in room temperature, refrigerator or freezer. Calibration curves were only run for 
the long-term stability samples. All data analysis was performed with MultiQuant™ 
software under linear regression with a “1/x” weighting factor.  Among the three deuterated 
internal standards for the blood analytes, XLR11-d5 was used to quantify 5-fluoro-3,5-AB-
PFUPPYCA, EMB-FUBINACA, XLR11, 5-fluoro ADB-PINACA, MDMB-FUBICA, 
MEP-CHMICA and NM2201; PB-22-d9 for ADB-PINACA, APP-PICA and PB-22; 
UR144-d5 for 4-cyano CUMYL-BUTINACA, JWH-250, MO-CHMINACA, CUMYL-
THPINACA, 5-fluoro PY-PINACA, RCS-8 and UR144. Among the four deuterated 
internal standards for the urine metabolites, 5-fluoro PB-22 3-carboxyindole-d5 was used 
to quantify 5-fluoro MDMB-PICA metabolite 7, 5-fluoro PB-22 3-carboxyindole, AB-
FUBINACA metabolite 3, ADB-PINACA N-(4-hydroxypentyl), ADB-PINACA 
pentanoic acid, UR144 Degradant N-pentanoic acid and MDMB-FUBICA metabolite 3; 
PB-22-d9 for only PB-22 N-(5-hydroxypentyl); UR144-d5 for UR144 N-(5-
hydroxypentyl) and JWH-250 pentanoic acid.  
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3. RESULTS AND DISCUSSION 
3.1 Analysis of Blood with Sodium Fluoride Preservative Samples 
 Percentage of analyte degradation was determined by calculating the ratio between 
the average area ratio of the analyte and ISTD at 0 hour and each time point. In general, 
synthetic cannabinoids were considered stable if the average area ratio of the select time 
point was within ±20% of the initial area ratio. In some cases, analytes were considered 
stable if an overall stability pattern between the low and high concentration levels was 
observed. For example, if the high concentration samples were within the ±20% range but 
the low level was ±30%, the analyte in some cases was considered stable for that specific 
time point.  Table 16 encompasses the finalized results of the select seventeen SCs in blood 
preserved with sodium fluoride at all three temperature conditions. Although JWH-250 had 
similar degradation results, UR144 was the most consistently stable synthetic cannabinoid 
up to 35 weeks under all storage conditions. APP-PICA was the least stable analyte which 
degraded after only 1 week at all storage conditions. 
Majority of the analytes were found to be stable at 35 weeks using the ±20% area 
ratio criteria and overall stability trend observed when stored in the freezer. In comparison 
to samples stored under room temperature, freezing the preserved blood samples appears 
to slow down the degradation process with exception of APP-PICA. All analytes in the 
sodium fluoride preserved blood were stable at 21 to 35 weeks in the freezer, with the 
exception of APP-PICA. 
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Table 16: Summary of the Stability Results for Blood with Sodium Fluoride. 
Analytes with two time points refer to the low (top) and high (below) concentration results. 
 
Synthetic Cannabinoids Room Temp Fridge Freezer 
4-cyano CUMYL-BUTINACA 24 hours 3 weeks 35 weeks 
ADB-PINACA 
21 weeks low, 
17 weeks high 
35 weeks 35 weeks 
EMB-FUBINACA 0 hours 
72 hours low, 
24 hours high 
21 weeks 
JWH-250 35 weeks 35 weeks 35 weeks 
MO-CHMINACA 35 weeks 3 weeks 35 weeks 
5-fluoro-3,5-AB-PFUPPYCA 
24 hours low, 
21 weeks high 
17 weeks low, 
35 weeks high 
35 weeks 
5-fluoro ADB-PINACA 0 hours 
0 hours low,  
72 hours high 
24 hours low, 
21 weeks high 
APP-PICA 1 week 1 week 
24 hours low, 
1 week high 
CUMYL-THPINACA 35 weeks 17 weeks 
17 weeks low, 
35 weeks high 
PB-22 3 weeks 35 weeks 35 weeks 
XLR11 24 hours 1 week 21 weeks 
5-fluoro PY-PINACA 35 weeks 35 weeks 35 weeks 
MDMB-FUBICA 
9 weeks low,  
1 week high 
35 weeks low, 
21 weeks high 
35 weeks low, 
21 weeks high 
MEP-CHMICA 72 hours 72 hours 21 weeks 
NM2201 
5 weeks low,  
3 weeks high 
35 weeks 
35 weeks low, 
17 weeks high 
RCS-8 21 weeks 35 weeks 35 weeks 
UR144 35 weeks 35 weeks 35 weeks 
 
 
Stability trends associated with the chemical structure of these analytes were 
discovered. Synthetic cannabinoids that were stable up to 35 weeks in freezer generally 
had a core structure of a carbonyl substituent on a pyrazole or pyrrole with surrounding 
nonpolar groups, such as hydrocarbons, benzene rings and heterocyclic rings as shown in 
Figure 3.  
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Figure 3: Structure of Analytes Stable up to 35 Weeks in Freezer. 
The pyrazole or pyrrole and carbonyl core is highlighted in dark gray whereas the 
neighboring nonpolar groups are shown in lighter gray. 
 
 
 
 
4-cyano CUMYL-BUTINACA 5-fluoro-3,5-AB-PFUPPYCA CUMYL-THPINACA 
  
 
JWH-250 PB-22 5-fluoro PY-PINACA 
 
  
NM2201 RCS-8 UR144 
 
Figure 4: Structure of Degraded Analytes at 1 Week or Earlier under Room 
Temperature and Refrigeration.  
The two adjacent carbonyl functional groups are highlighted in dark gray. 
 
    
EMB-FUBINACA APP-PICA MEP-CHMICA 5-fluoro ADB-PINACA 
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Unstable analytes that degraded at 1 week or earlier in room temperature and 
refrigerator generally had two polar carbonyl functional groups adjacent to one another. 
For example, the presence of two consecutive amides or an amide followed by an ester are 
illustrated in Figure 4. Further, 5-fluoropentyl analogs, like XLR11 and 5-fluoro ADB-
PINACA, degraded at earlier time points under all three storage temperatures in contrast 
with their complementary analyte, UR144 and ADB-PINACA.  
 
3.2 Analysis of Blood with EDTA Preservative Samples 
 In comparison to the blood preserved with sodium fluoride, all blood samples 
containing EDTA degraded much earlier under all storage conditions except for 5-fluoro 
ADB-PINACA, APP-PICA, and XLR11. Additional time points are necessary to 
accurately conclude how EDTA affects these three SCs in comparison to sodium fluoride. 
However, APP-PICA was found to be more stable in EDTA than sodium fluoride 
preservatives (1 week) under all temperatures.  
Table 17: Summary of the Stability Results for Blood with EDTA. 
Synthetic Cannabinoids Room Temp Fridge Freezer 
5-fluoro ADB-PINACA 0 hour 0 hour 3 weeks 
APP-PICA 3 weeks 3 weeks 3 weeks 
CUMYL-THPINACA 0 hour 0 hour 0 hour 
EMB-FUBINACA 0 hour 0 hour 0 hour 
MEP-CHMICA 0 hour 0 hour 0 hour 
NM2201 0 hour 0 hour 0 hour 
XLR11 72 hours 1 week 3 weeks 
 
Degradation outside of the ± 20% stability range was observed for the majority of 
the seven analytes as early as 24 hours. Therefore, it is recommended to use sodium 
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fluoride preservatives over EDTA in order to stabilize and therefore properly identify and 
quantify synthetic cannabinoids. Further, analyte stability for CUMYL-THPINACA, 
MEP-CHMICA and NM2201 in blood preserved with EDTA did not improve in 
comparison to the nonpreserved blood results.  
 
3.3 Analysis of Blood without Preservative Samples 
The majority of synthetic cannabinoids decreased in area ratio at earlier time points 
in non-preserved blood than preserved blood. Results are consistent with the 
recommendation to use additives and preservatives since it can often delay sample 
degradation and prevent blood clot formation. The most stable analyte in non-preserved 
blood, 5-fluoro-3,5-PFUPPYCA, had minimal degradation for up to 17 weeks under all 
three storage conditions. EMB-FUBINACA, on the other hand, was not stable and rapidly 
degraded more than ±20% within the first 24 hours under all storage temperatures. Some 
synthetic cannabinoids, such as PB-22, had completely different results in preserved blood 
from the data obtained for non-preserved blood. PB-22 was stable for 3 weeks in room 
temperature and 35 weeks in the refrigerator and freezer in sodium fluoride preserved blood 
as opposed to lasting only 72 hours and 9 weeks respectively in non-preserved blood. 
Analytes JWH-250 and MO-CHMINACA should be reevaluated for the freezing 
conditions due to inconsistencies, resulting in a 0-hour stability time point. Despite the 
varying stability ranges, no synthetic cannabinoids were stable at 35 weeks for the 
nonpreserved blood samples which further demonstrates the necessity to properly preserve 
blood for forensic casework backlogs or long-term biological specimen storage. 
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Table 18: Summary of the Stability Results for Blood without Preservative. 
Analytes with two time points refer to the low (top) and high (below) concentration results. 
 
Synthetic Cannabinoids Room Temp Fridge Freezer 
4-cyano CUMYL-BUTINACA 9 weeks 21 weeks 21 weeks 
ADB-PINACA 72 hours 72 hours 
24 hours low,  
0 hours high 
EMB-FUBINACA 0 hours 0 hours 0 hours 
JWH-250 3 weeks 21 weeks 0 hours 
MO-CHMINACA 72 hours 1 week 0 hours 
5-fluoro-3,5-AB-PFUPPYCA 17 weeks 17 weeks 17 weeks 
5-fluoro ADB-PINACA 0 hours 24 hours 
21 weeks low, 
0 hours high 
APP-PICA 72 hours 1 week 1 week 
CUMYL-THPINACA 3 weeks 21 weeks 21 weeks 
PB-22 72 hours 9 weeks 
9 weeks low, 
35 weeks high 
XLR11 72 hours 1 week 
24 hours low, 
21 weeks high 
 
Mix 3 analytes were reevaluated due to the inconsistent results that may have been 
caused by the presence of excessive amounts of blood clots found in the aliquoted samples. 
All of these synthetic cannabinoids were completed degraded past ±20% at nearly all time 
points and storage conditions. Therefore, a 3-week short-term stability of the Mix 3 
analytes was performed to reassess the inconsistent issues.  
 
Table 19: Summary of the Stability Results for Blood without Preservative Mix 3. 
 
Synthetic Cannabinoids Room Temp Fridge Freezer 
5-fluoro PY-PINACA 1 week 3 weeks 3 weeks 
MDMB-FUBICA 3 weeks 3 weeks 3 weeks 
MEP-CHMICA 24 hours 72 hours 3 weeks 
NM2201 24 hours 72 hours 3 weeks 
RCS-8 3 weeks 3 weeks 3 weeks 
UR144 3 weeks 3 weeks 3 weeks 
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 Further, the reevaluation of the Mix 3 synthetic cannabinoids in blood without 
preservatives had improved significantly as shown in Table 19. The most stable analytes 
were MDMB-FUBICA, RCS-8, and UR144 at 3 weeks under all storage temperatures 
whereas the least stable synthetic cannabinoid includes NM2201 and MEP-CHMICA. 
Degradation associated with the storage conditions correlated with first occurring under 
room temperature and decreased with colder storage temperatures.  
 
3.4 Analysis of Urine with Sodium Fluoride Preservative Samples 
 There were no significant changes observed to the stability with the addition of 1% 
sodium fluoride preservatives for 5-fluoro PB-22 3-carboyxindole, AB-FUBINACA 
metabolite 3, UR-144 Degradant N-pentanoic acid and MDMB-FUBICA metabolite 3. 
Under room temperature, PB-22 N-(5-hydroxypentyl) was less stable in urine preserved 
with sodium fluoride than urine without any additives. Additional time points for these 
synthetic cannabinoids are recommended to more accurately determine the long-term 
effects on whether the preservatives improve the stability of synthetic cannabinoids in urine 
or not. Synthetic cannabinoid metabolites 5-fluoro MDMB-PICA metabolite 7, ADB-
PINACA N-(4-hydroxypentyl) and JWH-250 N-pentanoic acid were less stable with 
sodium fluoride preservatives under all storage temperature conditions. Metabolite ADB-
PINACA pentanoic acid should be reevaluated as a result of inconsistent data between time 
points and was not included in the results (Table 20). 
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Table 20: Summary of the Stability Results for Urine with Sodium Fluoride. 
Synthetic Cannabinoids Room Temp Fridge Freezer 
5-fluoro MDMB-PICA Met. 7 24 hours 24 hours 24 hours 
5-fluoro PB-22 3-carboxyindole 3 weeks 3 weeks 3 weeks 
AB-FUBINACA Met. 3 3 weeks 3 weeks 3 weeks 
ADB-PINACA N-(4-hydroxypentyl) 72 hours 1 week 1 week 
JWH-250 N-pentanoic acid 24 hours 72 hours 72 hours 
UR-144 Degradant N-pentanoic acid 3 weeks 3 weeks 3 weeks 
PB-22 N-(5-hydroxypentyl) 72 hours 3 weeks 3 weeks 
MDMB-FUBICA Met. 3 3 weeks 3 weeks 3 weeks 
 
3.5 Analysis of Urine without Preservative Samples 
 The detectability of the metabolites in urine appears to be significantly less 
consistent than in sodium fluoride preserved blood across all storage conditions in which 
the overwhelming majority of the metabolites were stable for 9 weeks in room temperature, 
refrigerator and freezer. Although the synthetic cannabinoids may be identifiable up to 9 
weeks, these analytes were often unstable and did not always quantitate accurately after 
certain time points. For example, JWH-250 N-pentanoic acid was within the ±20% at 24 
hours and 17 weeks but quantifies just outside of the range at the time points in between, 
making it somewhat difficult to determine the exact time point of stability. Metabolites 
could be considered stable in some cases if the concentration fell within ±30% and an 
overall stability data trend was observed, Analytes were separated into different mixes in 
order to avoid potential ion suppression or ion enhancement from occurring as coeluting 
compounds present in a sample matrix may react, causing variance in analyte response in 
biological matrices like urine or blood (49, 50). Metabolites with similar retention times 
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and/or MRM transitions were split into different mixes in order to prevent any possible 
interferences with other analytes. 
Table 21: Summary of the Stability Results for Urine without Preservative. 
Analytes with two time points refer to the low (top) and high (below) concentration results. 
 
Synthetic Cannabinoids Room Temp Fridge Freezer 
5-fluoro MDMB-PICA Met. 7 35 weeks 35 weeks 35 weeks 
5-fluoro PB-22 3-carboxyindole 35 weeks 35 weeks 35 weeks 
AB-FUBINACA Met. 3 9 weeks 9 weeks 9 weeks 
ADB-PINACA N-(4-hydroxypentyl) 9 weeks 9 weeks 9 weeks 
ADB-PINACA pentanoic acid 5 weeks 5 weeks 
5 weeks low, 
9 weeks high 
UR-144 Degradant N-pentanoic acid 17 weeks 17 weeks 17 weeks 
PB-22 N-(5-hydroxypentyl) 3 weeks 3 weeks 17 weeks 
MDMB-FUBICA Met. 3 9 weeks 9 weeks 9 weeks 
UR-144 N-(5-hydroxypentyl) 9 weeks 17 weeks 17 weeks 
JWH-250 N-pentanoic acid 3 weeks 
9 weeks low, 
17 weeks high 
17 weeks 
 
At 35 weeks, 5-fluoro PB-22 3-carboxyindole was the most stable metabolite in 
urine without preservatives under all storage conditions. ADB-PINACA pentanoic acid 
was determined to be the least stable metabolite which degraded after 5 to 9 weeks in 
freezer and 5 weeks under room temperature and refrigeration.  
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4. CONCLUSIONS 
4.1 Summary of Findings 
Supported liquid extraction was a successful sample preparation technique to obtain 
the analytes of interest while removing undesired matrix components. Extraction times 
were reduced from approximately 1 hour to 30 minutes by eliminating steps for 
conditioning and washing as in the case of solid phase extraction. The UFLC-MS/MS 
method for the quantification of synthetic cannabinoids was robust and reliable in its 
assessment of the stability of SCs with a total analysis run time of 8 minutes. All calibration 
curves had an R2 value above 0.99 and had been validated according to the Academy 
Standards Board (ASB) guidelines.   
For forensic toxicology laboratories that are overwhelmed with backlogged 
caseloads, it is recommended that biological specimens containing synthetic cannabinoids 
should always be kept frozen or refrigerated. Analytes 5-fluoro ADB-PINACA, EMB-
FUBINACA, and MEP-CHMICA had a significantly smaller degree of degradation when 
stored in the freezer, prolonging the stability from less than 72 hours to 21 weeks. The 
addition of sodium fluoride and potassium oxalate preservatives generally decreased the 
amount of analyte degradation and formation of excessive numbers of blood clots. The 
addition of EDTA preservatives did not improve the stability of SC analytes in comparison 
to non-preserved blood. Synthetic cannabinoids with a core structure of a carbonyl 
substituent on a pyrazole or pyrrole and surrounding nonpolar groups were considered the 
most stable in sodium fluoride preserved blood at 35 weeks when kept frozen. In contrast, 
compounds with two polar carbonyl functional groups rapidly degraded within 1 week or 
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less at room temperature and refrigerator storage conditions. 5-fluoropentyl analogs of the 
synthetic cannabinoids with the exact same core structure had lower area ratio counts at 
earlier time points when stored in room temperature, refrigerator, and freezer. The majority 
of the urine metabolites were consistently stable up to 9 weeks across all storage conditions. 
Addition of sodium fluoride preservatives did not significantly impact the stability of SC 
metabolites up to 3 weeks.  
 
4.2 Significance of Findings 
 Biological samples containing synthetic cannabinoids tend to experience less 
detrimental impacts on analyte stability when kept frozen. This information may prove to 
be significant especially when analyzing postmortem samples collected from a body found 
in warmer environments or a body that has undergone decomposition. Routine forensic 
laboratories should properly store toxicological specimens in order to avoid stability 
differences as a direct cause of variable storage temperatures. Long-term stability patterns 
based on the structure can help backlogged laboratories with analyzing these synthetic 
cannabinoids as well as close analogs.  
Although there is not extensive research available on the long-term stability of 
synthetic cannabinoids, the stability time points in this research for blood analyte analysis 
coincides with other literature papers. Most of the SC research papers available focus on 
the earlier synthetic cannabinoids that were discovered, such as the JWH analogs or 
cycloalkylindoles like UR144 and XLR11, in comparison to more novel SC analogs (3).  
Fort et al. proposes that UR144 does not degrade until after 12 weeks under all three storage 
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conditions whereas XLR11 is only stable in the freezer for 12 weeks (3). Additional time 
points after 12 weeks were not evaluated in this research article. Similarly, preserved blood 
samples of UR144 were found to be stable up to 35 weeks and XLR11 up to 21 weeks 
under the same storage conditions as previously described. Ammann et al. revealed that 
JWH-250 was stable for 42 days in plastic containers but did not proceed with additional 
time points (51, 52). For room temperature, refrigerator and freezer, the thesis research 
samples for JWH-250 were stable for 35 weeks, surpassing the 42-day stability as found in 
the literature data.  
Stability results for synthetic cannabinoid metabolites in urine may vary between 
research studies possibly due to matrix interferences or the extensive breakdown of parent 
compounds and metabolites. In a research paper published by Fraga et al., the average loss 
of the cannabinoid 11-nor-9-carboxy-Δ9-tetrahydrocannabinol (THC-COOH) increased 
when there was a lower concentration (53). In frozen samples of greater than 100 ng/mL, 
there was an average loss of 18.2 ± 5.2% after 3 years as opposed to 23.7 ± 9.4% in samples 
less than 100 ng/mL. Losses may also be contributed to cannabinoid molecules adsorbing 
to the surface of the polypropylene storage containers (53).  Since the research samples 
were prepared at 10 ng/mL for low and 25 ng/mL for high concentration, this may attribute 
to the reason that AB-FUBINACA Met. 3 and UR-144 degradant N-pentanoic acid were 
stable for 9 weeks in freezer but 17 weeks in room temperature and refrigerator. Davies et 
al. demonstrated that 100 ng/mL positive control samples of 5-fluoro PB-22 3-
carboxyindole were stable in the refrigerator and freezer for 216 days or about 31 weeks 
(54). The samples were hydrolyzed with β-glucuronidase solution prior to liquid-liquid 
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extraction and analysis by LC-MS/MS (54). Although further time points have yet to be 
evaluated, the thesis research samples of 5-fluoro PB-22 3-carboxyindole were similarly 
stable up to 35 weeks in urine at all temperatures.  
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5. FUTURE APPLICATIONS AND STUDIES 
 As new designer drugs with significantly different chemical structures continue to 
emerge, research into the stability of synthetic cannabinoids is imperative for proper data 
analysis of forensic casework. This research project provides the forensic community with 
a reliable method to evaluate the stability of 17 synthetic cannabinoids in human whole 
blood and 10 synthetic cannabinoid metabolites in urine. Results further demonstrate 
degradation patterns associated with temperature storage conditions as well as stability 
trends linked to the chemical structure of the analytes. Additional method development to 
encompass the assessment of the vast number of other cannabinoids in different matrices, 
such as oral fluid, should be investigated. Freeze-thaw cycles of the biological specimens 
is crucial to understand the effect of non-metabolic degradation for real casework samples 
(55). Lower temperature conditions should also be explored in order to test whether -60°C 
or -80°C could improve the stability of the synthetic cannabinoids that rapidly degrade 
regardless of being frozen. 
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APPENDIX A: CHROMATOGRAPHIC DATA 
Figure 5: Chromatograms of the 17 Synthetic Cannabinoid Analytes and 3 Internal 
Standards for Blood Stability Analysis. 
 
 
Figure 6: Chromatograms of the 10 Synthetic Cannabinoid Metabolites and 4 
Internal Standards for Urine Stability Analysis.  
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